The rise of hundreds of billions of market cap pharmaceutical companies! Fosun 35 innovative drug exposure, 17 new class 1 drugs bright eyes, 22 over-rated varieties over the screen.

After returning to the market value of 100 billion yuan, Fosun Pharma's 2020 half-year results showed that operating income was RMB14,028 million, down 1.02% YoY, net profit was RMB1,715 million, up 13.1% YoY, and research and development investment was RMB1,689 million, up 25% YoY.
so far Fosun Pharma has 22 varieties over-evaluated (13 for the first), 11 varieties of winning national collection.
Innovation research and development into the harvest period, Hanlikang monthly revenue exceeded 100 million yuan, the first introduction of small-molecule innovative drug Avaquopa, the second bio-similar drug querceta single anti-approved market;
half-year net profit exceeded 1.7 billion yuan, and fosun Pharma achieved operating income of RMB14,028 million in the first half of 2020, down 1.02% YoY, while net profit attributable to shareholders of listed companies was RMB1,715 million, up 13.1% YoY.
's three major sectors, pharmaceutical manufacturing and research and development revenue was RMB10,012 million, down 8.11% YoY, while medical device and medical diagnostics business revenue was RMB2,641 million, up 46.96% YoY, and medical services business revenue was RMB1,360 million, down 6.83% YoY.
profit growth mainly comes from: First, the contribution of new coronavirus nucleic acid testing kits, negative pressure ambulances and ventilators and other anti-epidemic products; Rabies vaccine sales increased significantly, lysoxi single anti-injection new production scale (2000L) was approved after the rapid increase in sales, the first half of the revenue of 224 million yuan, june monthly revenue exceeded 100 million yuan;
first half of this year, Fosun Pharma vigorously developed strategic products, perfected the "imitation combination" of drug research and development system, research and development investment to further strengthen.
investment in research and development during the reporting period was 1,689 million yuan, up 25.02% YoY, of which research and development spending was 1.204 billion yuan, up 41.81% YoY.
recent years Fosun Pharma research and development investment (units: 100 million yuan) as the old pharmaceutical white horse shares, Fosun Pharma has not been much attention to the capital market.
in previous years of frenzied mergers and acquisitions, Fosun Pharma's share price soared, toping 100 billion yuan at the end of 2017 for the first time and plummeting to $57.9 billion at the end of 2018.
2020, Fosun Pharma's share price will go up and its market value will return to 100 billion yuan.
22 over-rated varieties, 11 varieties into the market for generic drugs, 2020 so far Fosun Pharma only 3 varieties have been approved for listing, respectively, injection with lansola, toluene sulfonate soraphine tablets, hydrochloric acid beauty King Kong tablets; 6 varieties submitted to the market application, respectively, hydrochloric acid ilithycon injection, injection with right rezosheng, propofol medium / long chain fat milk injection, devassalban tablets, pyridric acid injection, hydrochloric acid lositin intestinal capsule.
Fosun Pharma has adopted/assimised through the consistent evaluation of generic drug consistency evaluation, so far Fosun Pharma has 22 varieties (38 regulations) through or as consistent evaluation.
8 of the 22 varieties were whole-body anti-infective drugs, 5 were nervous system drugs, cardiovascular drugs and digestive and metabolic drugs were 3 each.
From the evaluation order, Fosun Pharma 22 varieties of 13 for the first review, hydrochloric acid venlafasin tablets, hydrochloric acid amitin tablets, potassium chloride particles, alpha osteoalphrine tablets, Pikaruamine tablets and other 5 varieties for Fosun Pharma exclusive review.
the three batch of drug centralized belt procurement carried out in the country, Fosun Pharma has a total of 11 varieties of winning the bid.
, non-bustam tablets, pivastatin calcium tablets, aspirin tablets, etc. are the core products of Fosun Pharma, and revenue growth in 2020H1 remained high, with sales growth of 61.9%, 109.6% and 244.5%, respectively.
Fosun Pharma will adopt an effective product lifecycle management strategy for 11 varieties, thereby maintaining and improving the leading position of each product in the market segment.
the national volume procurement fosun medicine in the selection of 35 innovative drugs on the road! 17 new class 1 drugs bright eyes August 14, Fosun Pharma announced that the subsidiary Fuhong Hanxuan's injection of curvature bead monoanti (commodity name: Hanquyou) was approved by the State Drug Administration for the treatment of HER2-positive metastatic breast cancer, HER2-positive early breast cancer and HER2-positive metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.
the product is a biosynthic drug expected to sell more than $6 billion worldwide in 2019.
Is the second single-resistance product approved by Fosun Pharma, the company approved in February 2019 lytoxi monoanti (commodity name: Hanlikang) is China's first biosynthic drug.
2020H1 Hanlikang realized revenue of 224 million yuan, in June the monthly revenue exceeded 100 million yuan.
addition, Fosun Pharma's 3rd single-anti-product Adamo mono-anti-listing application is under review and has been included in the priority review process and is expected to be approved for listing this year.
Fosun Pharma is mainly in the research of new drugs up to now, Fosun Pharma is in the clinical stage of the main research of new drugs have 26.
from the registered classification, there are 17 new class 1 drugs.
from the drug type, 12 drugs for small molecule chemicals, 14 drugs for monoclonal antibody drugs.
From the research and development progress, the clinical phase III of recombinant anti-VEGF humanized monoclonal antibody injection metastatic colorectal cancer adaptation has been completed, and the clinical phase III of recombinant human mouse embedded anti-CD20 monoclonal antibody injection rheumatoid arthritis adaptation is in progress.
addition, Fosun Pharma's recombinant anti-PD-1 humanized monoclonal antibody injections have multiple combined treatment options in clinical trials in progress.
Fosun Pharma from external licensing of the introduction of products of the main research and development progress of 9 external licensing of the introduction of products, the first introduction of small-molecule innovative drug Malay acid avalancopa tablets to treat tumor chemotherapy caused by plateiac reduction clinical phase III, for chronic liver disease-related plateiac reduction has been approved for market;
mRNA vaccine was developed by Fosun Pharma in cooperation with BioNTech in Germany, bioNTech and Pfizer's cooperation abroad has entered clinical Phase II/III trials, and domestic data are expected to be used to speed up review and approval.
.